Send your LNP product development to lightspeed with the Sunny Suite

Significance of LNP Development

Lipid nanoparticles have transformed therapeutics by enabling rapid vaccine responses, in vivo gene editing, and targeted protein therapies. Consistent product quality from discovery through manufacturing is crucial to ensure safety and efficacy.

Objectives and Study Overview

This application note presents the Sunny Suite platform by Unchained Labs, which integrates high-throughput screening, process optimization, and GMP manufacturing for LNPs. The platform aims to streamline development workflows, maintain process fidelity, and reduce time and cost to clinic.

Methodology and Instrumentation

• Sunscreen microfluidic screening enables automated formulation testing in 96-well plates using sample volumes as low as 100 µL.
• Sunshine supports both protocol and continuous flow modes for flexible optimization and scale-up from 1 mL to multi-liter production.
• Sunbather provides GMP-ready continuous manufacturing with single-use or CIP flow paths, fully traceable consumables, and 21 CFR Part 11 compliant software.
• Stunner RADLS offers rapid QC analysis of particle size, distribution, and RNA content in 2 µL samples using a 96-well plate format.

All microfluidic chips are made of inert glass channels with ±5 nm surface roughness for fouling resistance and reproducible mixing. Continuous syringe pumps deliver identical flow performance across all devices, eliminating the need for re‐optimization during scale‐up.

Main Results and Discussion

A case study using an mFLuc mRNA-loaded LNP formulation demonstrated seamless method transfer across the Sunny Suite. Key outcomes include consistent particle size (80–100 nm), low polydispersity, and encapsulation efficiency above 90% on all instruments. Identical mixing conditions and pump performance ensured reproducible batches, minimizing waste and reducing development risk.

Benefits and Practical Applications

• End-to-end consistency with the same mixing and pumping technology from discovery to GMP manufacture.
• Regulatory compliance via traceable single-use flow paths and Part 11 software for audit trails.
• Resource efficiency through minimal sample consumption, reduced reagent costs, and faster timelines.
• User-friendly interfaces requiring minimal training and standardized consumables across platforms.

Future Trends and Opportunities

Advances in microfluidic design, automation, and integration with real-time analytics and machine learning are poised to further accelerate LNP development. The shift toward continuous biomanufacturing and disposable systems will support personalized medicines and rapid response platforms.

Conclusion

The Sunny Suite offers a unified workflow for LNP development, delivering reproducible performance from formulation screening through GMP production. By harmonizing process parameters and instrumentation, it lowers risk, time, and cost, facilitating faster delivery of life-changing therapies.

Reference

• Unchained Labs Application Note: Send your LNP product development to lightspeed with the Sunny Suite, Rev A, 2024.